REGN vs SABS
REGN: Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic areas. SABS: SAB Biotherapeutics produces fully human polyclonal antibodies via engineered cattle to treat autoimmune diseases, with SAB-142 in Phase 2b trials for type 1 diabetes.
Side-by-side fundamentals
| Metric | REGN | SABS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $651.18 | $3.58 | |
| Market cap as of 2026-07-23 | $70.6B | $278M | |
| P/E as of 2026-07-23 | 15.95 | 20.97 | REGN lower |
| PEG as of 2026-07-23 | 1.01 | n/a | |
| Net margin as of 2026-07-23 | +29.6% | -1795.8% | REGN higher |
| Gross margin as of 2026-07-23 | +85.7% | n/a | |
| Operating margin as of 2026-07-23 | +24.3% | -2388.9% | REGN higher |
| ROE as of 2026-07-23 | +14.3% | +15.2% | SABS higher |
| ROA as of 2026-07-23 | +11.1% | +12.5% | SABS higher |
| Debt / equity as of 2026-07-23 | 0.09 | 0.01 | SABS lower |
| Revenue growth (YoY) as of 2026-07-23 | +5.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +5.6% | n/a | |
| Dividend yield as of 2026-07-23 | +0.6% | n/a | |
| Beta as of 2026-07-23 | 0.21 | 0.56 | |
| 1-year return as of 2026-07-22 close | +16.1% | +34.8% | SABS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.